Gilteritinib
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Uma Maveli[2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
|
WARNING: DELAYED QT INTERVAL
See full prescribing information for complete Boxed Warning.
The delayed cardiac ventricular repolarization may require temporary discontinuation of Gilteritinib, and dosage reduction.
Patients should take an electrocardiogram to confirm proper heart rhythm prior to initializing Gilteritinib dosage, on days 8 and 15 of cycle 1, and before initiating the two successive cycles If the electrocardiogram results demonstrate a QTcF >500 msec, then patients should temporarily discontinue Gilteritinib and reduce the dosage. Patients should talk to their doctor about the dosage reduction. There is a QT prolongation risk for patients who show signs of Hypokalemia or hypomagnesemia. It is important to correct these problems before initiating Gilteritinib. These could be fixed with a potassium rich diet, but patients should talk to their doctor to address the severity and the following steps needed to take. |
Overview
Gilteritinib is a signal transduction inhibitor that is FDA approved for the treatment of given to adults who have relapsed into refractory acute myeloid leukemia. They would also have to have the mutation FLT3 which will be confirmed by an FDA-approved test. There is a Black Box Warning for this drug as shown here. Common adverse reactions include adverse reactions that more than 20% of the patients have are “myalgia/arthralgia, transaminase increase, fatigue/malaise, fever, noninfectious diarrhea, dyspnea, edema, rash, pneumonia, nausea, stomatitis, cough, headache, hypotension, dizziness and vomiting”. These are the most common. If there is suspicion of an adverse reaction, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Plasma Concentration
- After 15 days, the plasma concentration becomes steady
- Maximum Concentration: 374 ng/mL
- AUC: 6943 ng.h/mL
The Data is different in people who are fasting
- The Maximum Concentration decreased by 26%
- AUC decreased by 10%
Gilteritinib is indicated for
- Given to adult patients who have relapsed into refractory acute myeloid leukemia. They would also have to have the mutation FLT3 which will be confirmed by an FDA-approved test.
Limitations of Use
Recommended Vaccination and Prophylaxis
Recommended Weight-Based Dosage Regimen - PNH
Recommended Weight-Based Dosage Regimen - aHUS
Dosing Considerations
- It is recommended to start off a patient with a dose of 120 mg orally everyday. It does not matter if the patient has had food or not. The response to the medication could take up to 6 months, so keep the dosing going if the patient does not develop hypersensitivity, adverse reactions, or disease progression.
- DO NOT CRUSH OR BREAK THE XOSPATA TABLETS. Make sure to keep a scheduled time everyday to administer the pill. If it could not be administered at the correct time, the patient may take the medication on the same day, as long as it is 12 hours before the next dose.
- Some dosing modifications include:
- If the adverse reaction of Posterior Reversible Encephalopathy Syndrome occurs, DISCONTINUE Gilteritinib
- If pancreatitis is present, temporarily stop Gilteritinib until pancreatitis is resolved. To start up the medication, give patients a daily dose of 80 mg.
Preparation of GILTERITINIB
Administration of GILTERITINIB
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding GILTERITINIB Off-Label Guideline-Supported Use and Dosage (Adult) in the drug label.
Non–Guideline-Supported Use
There is limited information regarding GILTERITINIB Off-Label Non-Guideline-Supported Use and Dosage (Adult) in the drug label.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding GILTERITINIB FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding GILTERITINIB Off-Label Guideline-Supported Use and Dosage (Pediatric) in the drug label.
Non–Guideline-Supported Use
There is limited information regarding GILTERITINIB Off-Label Non-Guideline-Supported Use and Dosage (Pediatric) in the drug label.
Contraindications
Gilteritinib is contraindicated in patients that seem to react badly to the medicine or any of its ingredients. Check the package label to get more information on the ingredients. It is important to note that clinical studies have shown effects of anaphylactic reactions.
Warnings
|
WARNING: DELAYED QT INTERVAL
See full prescribing information for complete Boxed Warning.
The delayed cardiac ventricular repolarization may require temporary discontinuation of Gilteritinib, and dosage reduction.
Patients should take an electrocardiogram to confirm proper heart rhythm prior to initializing Gilteritinib dosage, on days 8 and 15 of cycle 1, and before initiating the two successive cycles If the electrocardiogram results demonstrate a QTcF >500 msec, then patients should temporarily discontinue Gilteritinib and reduce the dosage. Patients should talk to their doctor about the dosage reduction. There is a QT prolongation risk for patients who show signs of Hypokalemia or hypomagnesemia. It is important to correct these problems before initiating Gilteritinib. These could be fixed with a potassium rich diet, but patients should talk to their doctor to address the severity and the following steps needed to take. |
Serious Meningococcal Infections
Other Infections
Monitoring Disease Manifestations after GILTERITINIB Discontinuation
Infusion Reactions
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Gilteritinib Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Gilteritinib Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Gilteritinib Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There are no available data on GILTERITINIB use in pregnant women to inform a drugassociated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Gilteritinib in women who are pregnant.
Labor and Delivery
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Nursing Mothers
There is no FDA guidance on the use of Gilteritinib in women who are nursing.
Pediatric Use
The safety and efficacy of GILTERITINIB for the treatment of PNH in pediatric patients have not been established.
Geriatic Use
Clinical studies of GILTERITINIB did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Gender
There is no FDA guidance on the use of GILTERITINIB with respect to specific gender populations.
Race
There is no FDA guidance on the use of GILTERITINIB with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of GILTERITINIB in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of GILTERITINIB in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of GILTERITINIB in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of GILTERITINIB in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Gilteritinib Administration in the drug label.
Monitoring
There is limited information regarding Gilteritinib Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Gilteritinib and IV administrations.
Overdosage
There is limited information regarding Andexanet alfa overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
Gilteritinib
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | 188303.705 Da |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Mechanism of Action
There is limited information regarding Gilteritinib Mechanism of Action in the drug label.
Structure
There is limited information regarding GILTERITINIB Structure in the drug label.
Pharmacodynamics
Pharmacokinetics
- Inhibited the receptor tyrosine kinase which regulates FLT3 in acute myeloid luekemia
Trials Phase 1 and 2:
- Complete response: 41%
- Overall Response Rate: 52%
- Duration of Response(Median): 20 weeks
- Overall Survival(Median): 31 weeks
Phase 3:
- Complete Remission
- Complete Remission with limited blood recovery: 21% of patients
Distribution
- Central Volume of Distribution is approximately 1092 L
- Peripheral Volume of Distribution is approximately 1100 L
Elimination
- About 64.5% of the administered dose is excreted in the feces
- About 16.4% of the administered dose goes through the urine
Specific Populations
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
Clinical Studies
The medicinal value of Gilteritinib was analyzed from five clinical trials Results:
- Elimination was through feces
- Exposure to the drug (effectiveness) was similar with and without fasting
- Administering Gilteritinib with itraconazole(strong P-glycoprotein and CYP3A4 inhibitor) or rifampicin(strong P-glycoprotein and CYP3A inducer) lowered the effectiveness of the drug and altered its structure
- Administering Gilteritinib with midazolam(CYP3A4 substrate) did not alter the effectiveness
- Hepatic impairment(liver impairment) does not affect the unbound exposure of the drug
How Supplied
- The authorized dose for patients on Gilteritinib is 120 mg but may go up to 200 mg is the response from the patient is dissatisfactory
Storage
There is limited information regarding Gilteritinib Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Gilteritinib |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Gilteritinib |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
It is recommended that patients read the FDA-approved patients labelling.
Posterior Reversible Encephalopathy Syndrome
There is a risk that patients may develop Posterior Reversible Encephalopathy Syndrome. Clinical studies and patient reactions have shown rare cases of this reaction. Patients should immediately report any symptoms of PRES to their doctors. These symptoms may include, but are not limited to, seizures and an altered mental status. The medical practitioner will bring the patient in for further evaluation.
Prolonged QT Interval
There is a slightly higher risk patients may develop a prolonged cardiac ventricular depolarization. FDA reports that about 8% of patients in the clinical trial have a period of prolongment greater than 60 milliseconds. If patients find symptoms such as feeling faint, losing consciousness, or arrhythmia, it is recommended they go see a healthcare professional immediately. Patients who may find signs/ symptoms or have a history with hypokalemia or hypomagnesemia should be made aware of the importance of monitoring their electrolytes.
Pancreatitis
Pancreatitis development is rare solely based on taking Gilteritinib. Medical practitioners should advise patients of the risk of developing this disease, and research the symptoms associated with it. Patients should immediately call their doctor if any of the signs arise. Some of the signs and symptoms of pancreatitis include “severe and persistent stomach pain, with or without nausea and vomiting”
Discontinuation
Infusion reactions
Precautions with Alcohol
Alcohol-Gilteritinib interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
Xospata
Look-Alike Drug Names
There is limited information regarding GILTERITINIB Look-Alike Drug Names in the drug label.
Drug Shortage Status
Drug Shortage
Price
References
The contents of this FDA label are provided by the National Library of Medicine.